Beacon Investment Advisory Services Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Beacon Investment Advisory Services Inc. cut its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 3,721 shares of the biopharmaceutical company’s stock after selling 680 shares during the period. Beacon Investment Advisory Services Inc.’s holdings in Alnylam Pharmaceuticals were worth $876,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Huntington National Bank increased its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $29,000. Washington Trust Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $42,000. True Wealth Design LLC raised its stake in shares of Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $45,000. Institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ALNY. Barclays upped their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Sanford C. Bernstein cut their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Finally, Scotiabank increased their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $298.61.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,122 shares of company stock valued at $2,540,455. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Trading Up 3.4 %

Shares of ALNY opened at $275.54 on Friday. The firm has a market cap of $35.54 billion, a P/E ratio of -105.17 and a beta of 0.34. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a 50 day simple moving average of $246.27 and a two-hundred day simple moving average of $260.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same period last year, the firm earned $1.15 earnings per share. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.18 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.